Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

<p>Gene Expression-RNAseq. Summary gene expression data of the individual tumors included in Fig. 5a-c.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Renzo Perales-Linares (17314863) (author)
Kolejni autorzy:	Nektaria Maria Leli (17314866) (author), Hesham Mohei (17314869) (author), Silvia Beghi (17314872) (author), Osvaldo D. Rivera (17314875) (author), Nektarios Kostopoulos (17314878) (author), Andrea Giglio (17314881) (author), Subin S. George (17314884) (author), Mireia Uribe-Herranz (17314887) (author), Francesca Costabile (17314890) (author), Stefano Pierini (17314893) (author), Sergei Pustylnikov (17314896) (author), Giorgos Skoufos (14865857) (author), Yoseph Barash (15130157) (author), Artemis G. Hatzigeorgiou (17314899) (author), Constantinos Koumenis (14865905) (author), Amit Maity (17314902) (author), Michael T. Lotze (14937723) (author), Andrea Facciabene (17314905) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Tumor Biology Immuno-oncology Immunology Tumor resistance to immune response Immunotherapy Combination immunotherapy Progression, Invasion & Metastasis Tumor progression
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
od: Renzo Perales-Linares (17314863)
Wydane: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
od: Francisco Hermida-Prado (14958909)
Wydane: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
od: Renumathy Dhanasekaran (14962092)
Wydane: (2025)

Supplementary Table1 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
od: Yidan Ren (14845140)
Wydane: (2025)

Supplementary Table2 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
od: Yidan Ren (14845140)
Wydane: (2025)

Supplementary Table3 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
od: Yidan Ren (14845140)
Wydane: (2025)

Supplementary Table 7_Genes identified by differential expression analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Wydane: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
od: Xufeng Lu (14960724)
Wydane: (2025)

Supplementary Table 6_Gene modules analysis_GO and curated pathways associated to gene modules from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Wydane: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
od: Isha Mondal (16721699)
Wydane: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
od: Carlotta Antoniotti (15352506)
Wydane: (2025)

Supplementary Table 9_Pro metastatic pathways identified by differential expression singlePT setting from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
od: Niccolò Roda (16437288)
Wydane: (2025)

Figure 1 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 4 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 5 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 6 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_1bg0t2bhh1nje8piu0g4juc5gh